Breakthrough Partnership: Dr. Reddy’s and Takeda Join Forces to Launch India’s First Dengue Vaccine, QDENGA

In a landmark development for public health in India, Dr. Reddy’s Laboratories Ltd. and Takeda Pharmaceutical Company Limited have officially entered into a strategic distribution agreement. Under this collaboration, Dr. Reddy’s will exclusively promote and distribute Takeda’s groundbreaking dengue vaccine, QDENGA (TAK-003), across India’s private pediatric and adult healthcare markets. Pending final local administrative and regulatory processes, the vaccine is anticipated to roll out commercially in the first half of 2027.

This partnership arrives on the heels of a major regulatory milestone: the Central Drugs Standard Control Organization (CDSCO) granted marketing authorization for QDENGA in July 2026 for individuals aged 4 to 60 years. As the country’s very first approved vaccine against dengue, it offers a vital new tool to combat a rapidly escalating health crisis.

Addressing India’s Growing Dengue Epidemic

Dengue continues to pose a formidable and evolving challenge across India, with reported cases surging eleven-fold over the past two decades. A nationwide surveillance study by the Indian Council of Medical Research’s Virus Research and Diagnostic Laboratory reveals a complex transmission landscape: all four dengue virus serotypes (DENV-1 through DENV-4) are co-circulating across multiple regions, with approximately 1 in 14 patients experiencing concurrent multi-serotype infections. With transmission occurring year-round, robust preventive measures have never been more urgent.

Leadership from both pharmaceutical giants emphasized the significance of the alliance:

M.V. Ramana, CEO of Global Generics at Dr. Reddy’s Laboratories, noted the company’s pride as the second-largest vaccine player in India, highlighting that making QDENGA accessible will play a crucial role in easing the nation’s severe dengue burden.
Dr. Mahender Nayak, Head of Intercontinental Markets at Takeda, underscored the company’s commitment to meeting India’s evolving healthcare needs. He noted that while Takeda welcomes recent Parliamentary Committee recommendations to explore inclusion in the Universal Immunization Program, private-market availability through Dr. Reddy’s ensures immediate, timely access for eligible populations.

Complementary Strengths and Operational Scope

The collaboration pairs Takeda’s extensive global expertise in vaccine science, regulatory affairs, disease education, and brand strategy with Dr. Reddy’s robust commercial footprint and distribution network in India.

Dr. Reddy’s Role: Exclusively drives private-market promotion, medical and healthcare-professional engagement, disease awareness initiatives, and broad distribution for both pediatric and adult populations.
Takeda’s Role: Retains legal ownership, overall medical and brand oversight rights, and maintains exclusive distribution rights for India’s public immunization programs.

About QDENGA (TAK-003)

QDENGA is a live-attenuated tetravalent dengue vaccine engineered on a DENV-2 backbone with structural proteins representing DENV-1, DENV-3, and DENV-4. This design delivers comprehensive immune coverage across all four circulating serotypes. Administered as a two-dose subcutaneous regimen three months apart, the vaccine is backed by an extensive global clinical program involving over 60,000 participants across eight dengue-endemic countries. The pivotal seven-year Phase 3 TIDES trial demonstrated sustained overall efficacy and safety across diverse populations worldwide.